癌症治疗靶向递药的进展与挑战。
Progress and challenges towards targeted delivery of cancer therapeutics.
机构信息
Laboratory of Precision NanoMedicine, School of Molecular Cell Biology and Biotechnology, George S. Wise Faculty of Life Sciences, Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering; Center for Nanoscience and Nanotechnology, Cancer Biology Research Center, Tel Aviv University, Tel Aviv, 6997801, Israel.
Center for Nanomedicine and Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA.
出版信息
Nat Commun. 2018 Apr 12;9(1):1410. doi: 10.1038/s41467-018-03705-y.
Targeted delivery approaches for cancer therapeutics have shown a steep rise over the past few decades. However, compared to the plethora of successful pre-clinical studies, only 15 passively targeted nanocarriers (NCs) have been approved for clinical use and none of the actively targeted NCs have advanced past clinical trials. Herein, we review the principles behind targeted delivery approaches to determine potential reasons for their limited clinical translation and success. We propose criteria and considerations that must be taken into account for the development of novel actively targeted NCs. We also highlight the possible directions for the development of successful tumor targeting strategies.
在过去几十年中，癌症治疗的靶向递送方法有了显著的发展。然而，与大量成功的临床前研究相比，只有 15 种被动靶向纳米载体（NCs）被批准用于临床应用，没有一种主动靶向 NC 能够通过临床试验。本文综述了靶向递药方法的原理，以确定其临床转化和成功的潜在原因。我们提出了开发新型主动靶向 NC 必须考虑的标准和注意事项。我们还强调了成功的肿瘤靶向策略的可能发展方向。
Zotero 插件